How diagnostic innovation is improving access and early disease detection

Early diagnosis is one of the most powerful strategies in modern healthcare. Yet too often, fear, discomfort and stigma prevent people from taking part in traditional screening programmes. Research is therefore increasingly focusing not only on the clinical accuracy of diagnostic tools, but also on how these tools can better accommodate the realities of patients’ lives. From at-home sampling kits to AI-supported imaging, a new generation of technologies is being developed to prioritise patient comfort and accessibility. 

A new approach to cervical screening

The traditional ‘smear test’ is currently the standard method for screening for cervical cancer.¹ This tests for the presence of human papillomavirus (HPV) - the virus responsible for more than 99.7% of cervical cancers - via a cervical swab which samples cells from the cervix for analysis.¹ However, despite its proven effectiveness, participation is not maximal due to factors such as lack of health awareness, fear of pain, as well as religious and cultural factors which can hinder some women’s acceptance of screening.^1,2

With a view to combat these challenges, a large-scale study conducted in China recently investigated a new method of HPV testing via menstrual blood collection using sanitary pads.² This study reported that samples of menstrual blood can detect high-risk HPV infections and precancerous changes with similar accuracy to clinician-collected cervical samples in real-world screening settings.²

This new method is non-invasive and samples can be self-collected at home, which means it has the potential to reach people who avoid or delay screening due to fear of pelvic exams, privacy concerns, or logistical barriers such as inability to attend clinics.² By offering a more convenient, more private, and less invasive option, this innovation reflects the kind of approach that could potentially help reduce barriers to screening participation among the ~30% of women in the UK who currently do not attend scheduled appointments.^2,3

Self-sampling and home testing for HPV

The menstrual blood HPV test is part of a growing shift towards greater patient autonomy in diagnostics. Many national programmes are now offering self-sampling HPV kits that people can use at home.³ For example, NHS England plans to offer at-home HPV sampling kits to people overdue for cervical screening, prioritising those who are six months late for their appointment.¹ Unlike a traditional smear test, this home sampling is based on a vaginal swab to detect HPV. If positive, the individual would then need to go to a clinic to undergo the usual smear test to see if there are precancerous changes to the cervix.¹

In the United States, self-collected HPV tests have already been incorporated into official guidelines, allowing individuals to collect samples without a pelvic exam for certain age groups.⁴ This approach marks a major shift in healthcare and reflects how advances in diagnostic technology are moving toward a patient-first approach.⁴

Liquid biopsy for cancer detection

Innovation in diagnostic tools is of course not limited to cervical cancer. Across healthcare, researchers are exploring non-invasive, patient-friendly and more convenient methods to detect disease earlier and more efficiently.

The use of a liquid biopsy is one example, which works by analysing biomarkers such as circulating tumour cells and tumour DNA in blood samples to detect cancers.⁵ Unlike tissue biopsies (which are invasive, difficult to repeat, and limited to a single tumour site), liquid biopsies are minimally invasive and can be easily performed at multiple time points.⁵ This therefore enables healthcare professionals to monitor disease progression, treatment response and emerging resistance in real time, while also eliminating the invasive nature of extracting a tissue biopsy.⁵

The emerging role of artificial intelligence

Artificial intelligence (AI) is helping clinicians detect disease earlier and with greater precision. For example, AI-assisted mammography has been shown in a large Swedish study to improve early breast cancer detection and reduce the rate of later diagnoses by 12%, signalling potential for improved patient outcomes.⁶

AI algorithms are often faster and more accurate at spotting microscopic patterns and abnormalities that the human eye might miss. By enhancing image interpretation and pathology workflows, these AI systems can accelerate diagnoses while also improving accuracy and consistency.⁷

Beyond diagnosis, AI is also transforming personalised treatment decisions. By analysing large-scale genetic, molecular and imaging data, AI can predict which therapies are most likely to work for an individual patient while identifying resistance risks and potential side effects in advance.⁷ Together, these advances in AI are helping to shift oncology towards more precise, proactive and patient-centred care.⁷

Looking ahead

Diagnosis is not determined by accuracy alone, but also by how accessible the process is to those who need it most. For patients, these diagnostic advances mean fewer barriers, fewer invasive procedures and more control over their own health. They offer reassurance to those who may feel anxious about traditional screening and provide options for people who might otherwise go untested.

When diagnostics are designed to reflect real-world needs, participation increases, and more lives can be saved.

If you work in diagnostics - or another area of patient care or treatment development - and you would like help communicating with your target audiences as effectively as possible, please reach out to us, we’d love to hear from you. Together we can get your message heard. 

References:

1. Cancer Research UK. NHS England adding at-home HPV testing to the cervical screening programme Available at: https://news.cancerresearchuk.org/2025/06/24/at-home-hpv-testing-cervical-screening-programme/ (Accessed March 2026).

2. Tain X, Cao C, Wang L, et al. Testing menstrual blood for human papillomavirus during cervical cancer screening in China: cross sectional population based study. BMJ. 2026;392:e084831.

3. UK Government. Home testing kits for lifesaving checks against cervical cancer. Available at: https://www.gov.uk/government/news/home-testing-kits-for-lifesaving-checks-against-cervical-cancer (Accessed March 2026).

4. Washington Post. Advances in screening can save lives. https://www.washingtonpost.com/opinions/2025/12/18/cervical-cancer-self-testing-hpv/ (Accessed March 2026).

5. Song J, Ye X and Xiao H. Liquid biopsy entering clinical practice: Past discoveries, current insights, and future innovations. Critical Reviews in Oncology/Hematology. 2025;207:104613.

6. The Guardian. AI support in breast cancer screening: Fewer missed cancer cases. Available at: https://www.theguardian.com/science/2026/jan/29/ai-use-in-breast-cancer-screening-cuts-rate-of-later-diagnosis-by-12-study-finds (Accessed March 2026).

7. Li J, Zhang L, Yu Z et al. The impact of AI on modern oncology from early detection to personalized cancer treatment. NPJ Precision Oncology. 2026;10:69.